Success in the US for NZX-listed cancer diagnostics company Pacific Edge has lead to record revenues in the current half year, and a reduced loss margin.
The company has recently had its bladder cancer tests approved for American Medicare and Medicaid patients, which fed into a 50%
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
